Affimed N V Revenue Growth Rates (AFMD), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Affimed N v   (NASDAQ: AFMD)
 

AFMD's Revenue Growth by Quarter and Year

Affimed N V 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AFMD Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September -
2nd Quarter June 0.17
1st Quarter March 9.27
FY 9.44

AFMDs Annual Revenue
Affimed N V 's Revenue in the fiscal year 2023 $ 9.27 millions
Affimed N V 's Revenue in the fiscal year 2022 $ 46.32 millions
Affimed N V 's Revenue in the fiscal year 2021 $ 45.21 millions
Affimed N V 's Revenue in the fiscal year 2020 $ 31.76 millions
Affimed N V 's Revenue in the fiscal year 2019 $ 23.96 millions




AFMD Revenue second quarter 2024 Y/Y Growth Comment
Affimed N v in the second quarter 2024 achieved Revenue of $ 0.17 millions compare to recorded in same quarter a year ago.

Looking into second quarter 2024 results within Major Pharmaceutical Preparations industry 192 other companies have achieved higher Revenue growth. While Affimed N V ' s Revenue no change of 0% ranks overall at the positon no. 3469 in the second quarter 2024.


AFMD Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - - - -
3rd Quarter September - -80.59 % -33.45 % 261.92 %
2nd Quarter June - - - -
1st Quarter March -79.99 % 2.46 % 42.35 % 32.55 %
FY   - -9.74 % 21.96 % -

Financial Statements
Affimed N V 's second quarter 2024 Revenue $ 0.17 millions AFMD's Income Statement
Affimed N V 's second quarter 2023 Revenue $ 0.00 millions Quarterly AFMD's Income Statement


AFMD Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June -98.21 % - - -
1st Quarter March - - - -
FY (Year on Year)   - -9.74 % 21.96 % -


Back to AFMD Growth rate Comparisons >> Back to AFMD Growth rate Comparisons >>


Revenue second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #193
Healthcare Sector #514
Overall #3469

Revenue Y/Y Growth Statistics
High Average Low
42.33 % -2.5 % -79.99 %
(Dec 31 2021)   (Dec 31 2023)
Revenue second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #193
Healthcare Sector #514
Overall #3469
Revenue Y/Y Growth Statistics
High Average Low
42.33 % -2.5 % -79.99 %
(Dec 31 2021)   (Dec 31 2023)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Affimed N V 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
-100 % -100 % -100 %
0  


AFMD's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2024 Affimed N V disclosed fall in Revenue from the first quarter by -98.21% to $ 0.17 millions, from $ 9.27 millions achived in the previous reporting period.

Within Major Pharmaceutical Preparations industry 276 other companies have achieved higher Revenue quarter on quarter growth. While Affimed N V 's Revenue growth quarter on quarter, overall rank is 4345.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #277
Healthcare Sector #710
Overall #4345
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #277
Healthcare Sector #710
Overall #4345
Revenue Q/Q Growth Statistics
High Average Low
-100 % -100 % -100 %
0  


AFMD's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2024 Affimed N V disclosed fall in Revenue from the first quarter by -98.21% to $ 0.17 millions, from $ 9.27 millions achived in the previous reporting period.

Within Major Pharmaceutical Preparations industry 276 other companies have achieved higher Revenue quarter on quarter growth. While Affimed N V 's Revenue growth quarter on quarter, overall rank is 4345.


Affimed N V 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Dec 31 2021)		 12 Months Ending
(Dec 31 2020)		 12 Months Ending
(Dec 31 2019)
Cumulative Revenue 12 Months Ending $ 9.27 $ 46.32 $ 45.21 $ 31.76 $ 23.96
Y / Y Revenue Growth (TTM) -79.99 % 2.45 % 42.33 % 32.58 % -9.88 %
Year on Year Revenue Growth Overall Ranking # 3469 # 1562 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) -79.99 % 2.45 % 42.33 % 32.58 % -9.88 %
Seq. Revenue Growth (TTM) Overall Ranking # 3469 # 2060 # 0 # 0 # 0


Cumulative Revenue growth Comment
For the 12 months ended Dec 31 2023 Affimed N V reported a sharp drop in Revenue by -79.99% year on year, to $9 millions, compare to the 2.45% growth at Dec 31 2022.

In the Healthcare sector 513 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1562 to 3469.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 193
Healthcare Sector # 514
Overall # 3469

Revenue TTM Y/Y Growth Statistics
High Average Low
42.33 %
 -2.5 %
-79.99 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 193
Sector # 514
S&P 500 # 3469
Cumulative Revenue growth Comment
For the 12 months ended Dec 31 2023 Affimed N V reported a sharp drop in Revenue by -79.99% year on year, to $9 millions, compare to the 2.45% growth at Dec 31 2022.

In the Healthcare sector 513 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1562 to 3469.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 193
Healthcare Sector # 514
Overall # 3469

Revenue TTM Y/Y Growth Statistics
High Average Low
42.33 %
-2.5 %
-79.99 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 193
Sector # 514
S&P 500 # 3469




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
AFMD's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue sharp drop for the quarter ending Jun 30 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2024
Organon and Co -0.06%$ -0.062 millions
Royalty Pharma Plc-0.17%$ -0.174 millions
Repligen Corp-0.21%$ -0.207 millions
Whitehawk Therapeutics Inc -0.37%$ -0.371 millions
3m Company-0.45%$ -0.446 millions
T2 Biosystems Inc -0.61%$ -0.611 millions
Hcw Biologics Inc -0.63%$ -0.635 millions
Enhabit Inc -0.65%$ -0.648 millions
Sonoma Pharmaceuticals Inc -1.05%$ -1.050 millions
Encision Inc -1.36%$ -1.358 millions
Vaso Corporation-1.40%$ -1.399 millions
Teladoc Health Inc -1.53%$ -1.527 millions
Zimvie Inc -1.55%$ -1.549 millions
Alpha Pro Tech Ltd -1.65%$ -1.645 millions
Novavax inc -2.11%$ -2.107 millions
Agile Therapeutics Inc-2.23%$ -2.232 millions
Fresenius Medical Care Ag-2.33%$ -2.330 millions
Avantor Inc -2.36%$ -2.357 millions
Aspira Women s Health inc -2.81%$ -2.810 millions
Viatris Inc -3.11%$ -3.113 millions
Catheter Precision Inc -3.13%$ -3.125 millions
Nrc Health-3.15%$ -3.153 millions
Akoya Biosciences Inc -3.16%$ -3.158 millions
Neuronetics Inc -3.55%$ -3.547 millions
Mettler toledo International Inc -3.60%$ -3.601 millions
Prestige Consumer Healthcare Inc -4.18%$ -4.181 millions
Dentsply Sirona Inc -4.28%$ -4.280 millions
Waters Corporation-4.33%$ -4.327 millions
Accelerate Diagnostics Inc -4.39%$ -4.394 millions
Envista Holdings Corporation-4.50%$ -4.499 millions


About Affimed N V Revenue Growth Rates (AFMD), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Affimed N v (CIK 1608390).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-24-040310
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Affimed N v ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.